JP2021513077A5 - - Google Patents

Info

Publication number
JP2021513077A5
JP2021513077A5 JP2020542645A JP2020542645A JP2021513077A5 JP 2021513077 A5 JP2021513077 A5 JP 2021513077A5 JP 2020542645 A JP2020542645 A JP 2020542645A JP 2020542645 A JP2020542645 A JP 2020542645A JP 2021513077 A5 JP2021513077 A5 JP 2021513077A5
Authority
JP
Japan
Prior art keywords
dementia
subject
adm
level
adrenomedullin
Prior art date
Application number
JP2020542645A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019154900A5 (https=
JP2021513077A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/052982 external-priority patent/WO2019154900A1/en
Publication of JP2021513077A publication Critical patent/JP2021513077A/ja
Publication of JP2021513077A5 publication Critical patent/JP2021513077A5/ja
Publication of JPWO2019154900A5 publication Critical patent/JPWO2019154900A5/ja
Priority to JP2023174585A priority Critical patent/JP2024001208A/ja
Pending legal-status Critical Current

Links

JP2020542645A 2018-02-08 2019-02-07 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー Pending JP2021513077A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023174585A JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18155682 2018-02-08
EP18155682.0 2018-02-08
PCT/EP2019/052982 WO2019154900A1 (en) 2018-02-08 2019-02-07 Adrenomedullin (adm) for diagnosis and/or prediction of dementia and anti-adrenomedullin binder for use in therapy or prevention of dementia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023174585A Division JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Publications (3)

Publication Number Publication Date
JP2021513077A JP2021513077A (ja) 2021-05-20
JP2021513077A5 true JP2021513077A5 (https=) 2022-08-04
JPWO2019154900A5 JPWO2019154900A5 (https=) 2022-08-04

Family

ID=61188647

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020542645A Pending JP2021513077A (ja) 2018-02-08 2019-02-07 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー
JP2023174585A Pending JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023174585A Pending JP2024001208A (ja) 2018-02-08 2023-10-06 認知症の診断および／または予測のためのアドレノメデュリン（ａｄｍ）、ならびに認知症の治療または予防における使用のための抗アドレノメデュリンバインダー

Country Status (12)

Country Link
US (2) US20210302440A1 (https=)
EP (1) EP3749959A1 (https=)
JP (2) JP2021513077A (https=)
KR (1) KR102717599B1 (https=)
CN (2) CN111902721B (https=)
AU (1) AU2019219071A1 (https=)
BR (1) BR112020014940A2 (https=)
CA (1) CA3090736A1 (https=)
IL (1) IL276564A (https=)
MX (1) MX421834B (https=)
SG (1) SG11202006686SA (https=)
WO (1) WO2019154900A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220146538A (ko) 2020-02-26 2022-11-01 페아엠 테라그노스틱스 게엠베하 치료 목적을 위한 펩티딜글리신 알파-아미드화 모노옥시게나제 (pam)의 용도
CN115280148A (zh) 2020-02-26 2022-11-01 Pam治疗诊断有限公司 测定肽酰甘氨酸α-酰胺化单加氧酶(PAM)的方法及其用于诊断目的的用途
EP3871689A1 (en) * 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
US20210285949A1 (en) 2020-03-16 2021-09-16 Sphingotec Gmbh Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
CN120731367A (zh) 2023-03-17 2025-09-30 Pam治疗诊断有限公司 肽基甘氨酸α-酰胺化单加氧酶（PAM）的测定方法及其诊断用途
WO2025133203A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Compounds and methods for a long-lasting pam
WO2025133225A1 (en) 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
RU2004109222A (ru) 2001-08-30 2005-10-20 Байорексис Фармасьютикал Корпорейшн (Us) Слитые белки модифицированного трансферрина
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
DE102005036094A1 (de) * 2005-08-01 2007-02-08 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose von neurodegenerativen Erkrankungen
CA2620738C (en) 2005-08-31 2010-10-12 Ezaki Glico Co., Ltd. Tablet for removing tongue coating
DE102006027818A1 (de) * 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
DE102006060112A1 (de) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
US20110039343A1 (en) * 2008-02-01 2011-02-17 Brahms Aktiengesellschaft Method for the identification of patients in need of therapy having minor cognitive disorders and the treatment of such patients
EP3785735A1 (en) 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
MX2012002428A (es) 2009-08-27 2012-09-12 Covagen Ag Compuestos de union il-17 y usos medicos de los mismos.
AU2010332932B2 (en) 2009-12-14 2013-01-17 Navigo Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin
RU2569745C2 (ru) 2010-06-08 2015-11-27 Пиерис АГ Мутеины липокалина слезы, связывающие альфа il-4 r
FR2964103B1 (fr) * 2010-08-30 2018-11-23 Universite D'aix-Marseille Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament
DK2780717T3 (en) * 2011-11-16 2017-02-13 Sphingotec Gmbh ADRENOMEDULLINASSAYS AND METHODS FOR DETERMINING MODERN ADRENOMEDULLIN
PL2594588T3 (pl) * 2011-11-16 2014-11-28 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii
US20160230227A1 (en) * 2012-12-21 2016-08-11 The New York Stem Cell Foundation Methods of treating alzheimer's disease
EP4231018A3 (en) * 2016-07-08 2023-11-15 SphingoTec GmbH Adrenomedullin for assessing congestion in a subject with acute heart failure

Similar Documents

Publication Publication Date Title
JP2021513077A5 (https=)
JP2024001208A5 (https=)
Chanez et al. Corticosteroid reversibility in COPD is related to features of asthma.
Feehally et al. Tonsillectomy in a European cohort of 1,147 patients with IgA nephropathy
Dropcho Antiamphiphysin antibodies with small‐cell lung carcinoma and paraneoplastic encephalomyelitis
Winterkamp et al. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease
JP6457463B2 (ja) 処置方法
JP2016536332A5 (https=)
Yamaguchi et al. Enzyme‐linked immunosorbent assay of Pro‐gastrin‐releasing peptide for small cell lung cancer patients in comparison with neuron‐specific enolase measurement
WO2009038689A4 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
JP2008535494A5 (https=)
JP2017501977A (ja) 肺高血圧症を治療するための組成物および方法
JP2017509692A5 (https=)
CN115976196B (zh) ErbB3作为肺动脉高压生物标志物和治疗靶点的应用
JP2009515183A5 (https=)
EP4592679A1 (en) Use of discoidin domain receptor 2 in diagnosis of neurodegenerative diseases, and related computer readable medium
JP3095784B2 (ja) 炎症プロセスの病因を決定するための診断方法
JPWO2019154900A5 (https=)
WO2016065877A1 (zh) Cd166作为肝癌诊断血清标志物的应用及其试剂盒
KR102592460B1 (ko) 폐동맥고혈압 동물모델 및 이를 이용한 폐동맥고혈압 예방 또는 치료용 물질의 스크리닝 방법
WO2021221668A1 (en) Anti-sars-cov-2 monoclonal antibody compositions
WO2024154832A1 (ja) 全身性強皮症の検出方法
Hojs-Fabjan et al. Polyneuropathy in hemodialysis patients: the most sensitive electrophysiological parameters and dialysis adequacy
Ratziu et al. 729 Diagnostic value of biochemical markers (fibrotest) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease (NAFLD)
JP6116938B2 (ja) 新規な肺高血圧症のマーカー